On March 13, QINGSONG HEALTH (02661) officially launched the Zhengyuanfang MedClaw Skills Store, introducing 886 standardized Skills in its initial release. These cover eight core medical scenarios: clinical diagnosis and treatment, public health, medical imaging, medical laboratory testing, hospital management, nursing management, medical record management, and medication management. Public information indicates this is the first Skills Store of its kind in the healthcare industry. Against the backdrop of medical AI rapidly shifting from competition based on model capabilities to competition based on scenario capabilities, the launch of the Zhengyuanfang MedClaw Skills Store signifies QINGSONG HEALTH's further progression in solidifying evidence-based medical capabilities into standardized, callable, reusable, and extensible product units, advancing its platform-based strategy for medical AI.
From an industry trend perspective, the competitive focus for large language models in medical settings is transitioning from "whether they can answer" to "whether they can be embedded into real workflows." When physicians consult the latest guidelines, filter cutting-edge literature, compare evidence levels, or formulate case discussions and diagnostic references, they require not a single generalized response, but an entire professional capability chain designed around specific clinical tasks. The value of the Zhengyuanfang MedClaw Skills Store lies in encapsulating these high-frequency, essential evidence-based medical capabilities into standardized Skills. This shifts complex processes from ad-hoc configuration to productized invocation, propelling medical AI's evolution from a tool-based attribute towards a platform-based attribute.
In terms of specific product form, the 886 launched Skills are organized according to actual physician workflows, forming a capability system spanning the eight scenarios. In clinical diagnosis and treatment scenarios, relevant Skills can automatically construct a PICO framework around clinical questions, invoke multiple databases to complete systematic literature screening, and output structured summaries. In medication management scenarios, Skills can rapidly retrieve drug interactions, contraindications, and evidence-based usage recommendations. In medical record management scenarios, Skills can automatically generate evidence-based compliant discussion reports based on case data, complete with full citation chains. For medical professional users, this means a shift from "configuring prompts and toolchains" to "selecting and directly running Skills," significantly lowering the barrier to use.
Viewed within the company's overall strategy, the Skills Store is not an isolated action but a crucial component in the continuous rollout of QINGSONG HEALTH's medical AI product matrix. Previously, the company launched the evidence-based medicine intelligent agent "Zhengyuanfang" and the Zhengyuanfang·MedClaw collaborative system, completing an upgrade from single-turn Q&A to multi-agent collaboration. The launch of the Skills Store now further supplements the capability distribution and organization layer, enabling professional capabilities to be continuously accumulated, repeatedly invoked, and scaled. Consequently, QINGSONG HEALTH is progressively forming a three-tiered, progressively advancing medical AI product system: "Evidence-Based Hub – Collaborative Base – Skill Store," making its product matrix increasingly comprehensive.
More noteworthy for the market is that the launch of the Skills Store does not merely represent a new product addition; it is expected to enhance the synergistic efficiency between QINGSONG HEALTH's existing businesses. According to the company's public disclosures and market communications, QINGSONG HEALTH has already accumulated AI capabilities in areas such as health management, precision marketing, and intelligent underwriting, and is continuously promoting the application of AI in real-world health scenarios. The Skills Store extends these AI capabilities further from backend empowerment to frontend products, directly reaching the core professional user group of physicians. This also signifies that the "medical" component within the company's full-chain layout of "examination-medication-healthcare-insurance" has gained a stronger technological lever.
For a health technology company, this extension from point products to platform capability layers often holds greater strategic value than a single functional upgrade. From a capital market perspective, the sequential rollout of the AI product matrix is helping QINGSONG HEALTH build a new valuation narrative. On March 9, the company was officially included in the Hong Kong Stock Connect, meaning mainland investors can now directly trade its shares through the Shanghai-Hong Kong and Shenzhen-Hong Kong Connect schemes, which is expected to enhance both liquidity and investor reach. Simultaneously, market research reports indicate that on March 12, "Great Western Securities" initiated coverage on the company with a "Buy" rating and a target price of HK$261.97. For the market, such ratings are not merely price anchors; more importantly, they reflect institutions reassessing the growth potential of QINGSONG HEALTH's evolution from a digital health service platform to a medical AI platform.
Looking further, past market valuations for health tech companies have primarily revolved around traffic capabilities, service capabilities, and point-based monetization efficiency. However, with the successive launches of products like the evidence-based medicine intelligent agent, the collaborative system, and the Skills Store, QINGSONG HEALTH's business model is expanding further from a "health service platform" towards an "AI-driven platform company." Particularly under the combined catalysts of inclusion in the Stock Connect, initial institutional coverage, and the continuous refinement of the product matrix, the company's platform-based valuation logic is becoming clearer. If subsequent developments such as third-party Skill integration, physician-side penetration, and multi-scenario collaboration materialize further, the potential for market re-rating of its AI ecosystem value could continue to expand.
In comparison to international counterparts, platforms like Microsoft and Google already distribute AI applications through marketplace mechanisms, but most still operate primarily on a general platform supply or enterprise service logic, with relatively limited coupling to clinical decision-making scenarios. The differentiation of the Zhengyuanfang MedClaw Skills Store lies in its capability system being directly built upon the context of evidence-based medical work; the starting point for each Skill's design is a specific clinical problem, not a generic technical interface. This product organization method, grown from real medical tasks, helps improve the scenario adaptability of medical AI and lays the foundation for the company's future plans to open third-party access and build a more complete ecosystem.
QINGSONG HEALTH stated that the Skills Store will continue to expand Skill coverage around scenarios such as clinical diagnosis and treatment, research assistance, medical education, and multidisciplinary collaboration. It will also gradually open capabilities for third-party Skill integration, promoting the evolution of evidence-based medical capabilities from being "expert experience-driven" to "intelligent invocation-driven." Against the backdrop of the continuous rollout of the AI product matrix, strengthening business synergies, and rising capital market attention, QINGSONG HEALTH's medical AI strategy is gradually transitioning from a "technology investment phase" towards an "ecosystem value-release phase."
Comments